This proposal focuses on the functional expression of the oncogene sequences of two avian acute leukemia viruses, myelocytomatosis virus (MC29) and avian myeloblastosis virus (AMV). MC29 and AMV are replication defective leukemia viruses capable of inducing acute leukemias of various types as well as carcinomas and sarcomas. Cells transformed by these viruses display a distinct phenotype of differentiation. To investigate the structure and function of the MC29 oncogene (myc) and the AMV oncogene (myb), we will use recombinant DNA technology coupled with DNA modification techniques to alter the DNA sequence of molecular clone of MC29 and AMV. The isolation and characterization of engineered mutants and their reintroduction into cells via transfection procedures will permit us to assess the affects of specific mutations on myc andmyb gene expression. To facilitate the characterization of the myc and myb proteins and their normal cell counterparts, we propose to utilize bacterial expression of the respective myc and myb sequences as a means of obtaining large amounts of viral protein. These proteins will be used to raise antibodies to myc and myb specific determinants. Using the reagents generated above, namely a group of well-defined mutants and antisera to defined protein sequences, we propose to examine the expression of myc and myb gene products in fibroblast ad hematopoietic cells of normal and transformed origin. The understanding of the structure and function of oncogene proteins in essential for our ultimate knowledge of the mechanisms of oncogenesis. The combined genetic and biochemical approach to the definition of the structure and function of the myc and myb oncogenes should provide valuable information regarding this process.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA027578-06
Application #
3167711
Study Section
Experimental Virology Study Section (EVR)
Project Start
1980-05-01
Project End
1986-12-31
Budget Start
1985-05-01
Budget End
1986-12-31
Support Year
6
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Virginia
Department
Type
Schools of Medicine
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Huff, J L; Jelinek, M A; Jamieson, T A et al. (1996) Expression and maturation of the cellular sea receptor, a member of the hepatocyte growth factor (HGF) receptor family of protein tyrosine kinases. Oncogene 12:299-307
Huff, J L; Jelinek, M A; Borgman, C A et al. (1993) The protooncogene c-sea encodes a transmembrane protein-tyrosine kinase related to the Met/hepatocyte growth factor/scatter factor receptor. Proc Natl Acad Sci U S A 90:6140-4
Biegalke, B J; Heaney, M L; Bouton, A et al. (1987) MC29 deletion mutants which fail to transform chicken macrophages are competent for transformation of quail macrophages. J Virol 61:2138-42
Raymond, V W; Parsons, J T (1987) Identification of an amino terminal domain required for the transforming activity of the Rous sarcoma virus src protein. Virology 160:400-10
Morgan, J H; Parsons, J T (1986) Characterization of c-myc proteins from avian bursal lymphoma cell lines. Virology 150:178-86
Parsons, S J; McCarley, D J; Raymond, V W et al. (1986) Localization of conserved and nonconserved epitopes within the Rous sarcoma virus-encoded src protein. J Virol 59:755-8
Parsons, J T; Wilkerson, V; Parsons, S J (1986) Structural and functional motifs of the Rous sarcoma virus src protein. Gene Amplif Anal 4:1-19
Heaney, M L; Pierce, J; Parsons, J T (1986) Site-directed mutagenesis of the gag-myc gene of avian myelocytomatosis virus 29: biological activity and intracellular localization of structurally altered proteins. J Virol 60:167-76
Wilkerson, V W; Bryant, D L; Parsons, J T (1985) Rous sarcoma virus variants that encode src proteins with an altered carboxy terminus are defective for cellular transformation. J Virol 55:314-21
Morgan, J H; Papas, T S; Parsons, J T (1985) Isolation of antibodies specific for avian viral and cellular myc proteins. J Natl Cancer Inst 75:937-47